Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Abstract of this article Free
space
 arrow  Figures/Tables List
space
 arrow  Related articles in Annals
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Cook, D. J.
space
  arrow  Brun-Buisson, C.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

ARTICLE

Incidence of and Risk Factors for Ventilator-Associated Pneumonia in Critically Ill Patients

right arrow Deborah J. Cook, MD; Stephen D. Walter, PhD; Richard J. Cook, PhD; Lauren E. Griffith, MSc; Gordon H. Guyatt, MD; David Leasa, MD; Roman Z. Jaeschke, MD; and Christian Brun-Buisson, MD

15 September 1998 | Volume 129 Issue 6 | Pages 433-440

Background: Understanding the risk factors for ventilator-associated pneumonia can help to assess prognosis and devise and test preventive strategies.

Objective: To examine the baseline and time-dependent risk factors for ventilator-associated pneumonia and to determine the conditional probability and cumulative risk over the duration of stay in the intensive care unit.

Design: Prospective cohort study.

Setting: 16 intensive care units in Canada.

Patients: 1014 mechanically ventilated patients.

Measurements: Demographic and time-dependent variables reflecting illness severity, ventilation, nutrition, and drug exposure. Pneumonia was classified by using five methods: adjudication committee, bedside clinician's diagnosis, Centers for Disease Control and Prevention definition, Clinical Pulmonary Infection score, and positive culture from bronchoalveolar lavage or protected specimen brush.

Results: 177 of 1014 patients (17.5%) developed ventilator-associated pneumonia 9.0 ± 5.9 days (median, 7 days [interquartile range, 5 to 10 days]) after admission to the intensive care unit. Although the cumulative risk increased over time, the daily hazard rate decreased after day 5 (3.3% at day 5, 2.3% at day 10, and 1.3% at day 15). Independent predictors of ventilator-associated pneumonia in multivariable analysis were a primary admitting diagnosis of burns (risk ratio, 5.09 [95% CI, 1.52 to 17.03]), trauma (risk ratio, 5.00 [CI, 1.91 to 13.11]), central nervous system disease (risk ratio, 3.40 [CI, 1.31 to 8.81]), respiratory disease (risk ratio, 2.79 [CI, 1.04 to 7.51]), cardiac disease (risk ratio, 2.72 [CI, 1.05 to 7.01]), mechanical ventilation in the previous 24 hours (risk ratio, 2.28 [CI, 1.11 to 4.68]), witnessed aspiration (risk ratio, 3.25 [CI, 1.62 to 6.50]), and paralytic agents (risk ratio, 1.57 [CI, 1.03 to 2.39]). Exposure to antibiotics conferred protection (risk ratio, 0.37 [CI, 0.27 to 0.51]). Independent risk factors were the same regardless of the pneumonia definition used.

Conclusions: The daily risk for pneumonia decreases with increasing duration of stay in the intensive care unit. Witnessed aspiration and exposure to paralytic agents are potentially modifiable independent risk factors. Exposure to antibiotics was associated with low rates of early ventilator-associated pneumonia, but this effect attenuates over time.


A recent international prevalence study involving more than 1000 intensive care units indicated that pneumonia is responsible for almost half of the infections in critically ill patients in Europe [1]. Ventilator-associated pneumonia accounts for approximately 90% of infections in patients requiring assisted ventilation [2, 3]. An independent contribution to mortality conferred by ventilator-associated pneumonia was recently suggested [4, 5]. Although debate persists about the mortality attributable to ventilator-associated pneumonia among other causes of death in critically ill patients [1, 4-7], there is little doubt that ventilator-associated pneumonia causes substantial morbidity by increasing the duration of mechanical ventilation and intensive care unit stay [4, 5]. It is therefore important to understand the factors that are predictive of ventilator-associated pneumonia, to identify patients at highest risk, and to target these patients for the most effective preventive strategies as determined by randomized trials [8, 9].

Risk factors for nosocomial pneumonia have been evaluated in hospitalized elderly persons [10], heterogeneous groups of hospitalized patients breathing spontaneously or requiring assisted ventilation [11], and similar mixed populations admitted to the intensive care unit [2, 12-15]. Investigations in ventilated critically ill patients only are needed to identify independent predictors of ventilator-associated pneumonia. Most studies of risk factors for ventilator-associated pneumonia have been conducted at single institutions, and different predictors have been examined. In cohort studies using multivariable analyses [16-21], only reintubation [17, 19, 21] and antibiotic use [18, 20] were identified as risk factors in more than one report. However, a direct relation between antibiotics and pneumonia was found in one study [18], whereas an inverse relation was found in another [20].

We examined factors associated with ventilator-associated pneumonia. We explored baseline and time-dependent characteristics, including measures of illness severity, factors relating to mechanical ventilation, variables in the gastropulmonary route of infection, and drug exposure.


Methods
space
up arrowTop
dotMethods
down arrowResults
down arrowDiscussion
down arrowAuthor & Article Info
down arrowReferences

Patients

We used a multicenter national database of 1200 patients who received mechanical ventilation for 48 hours or more and were enrolled from October 1992 to May 1996 in a double-blind, concealed, randomized trial of sucralfate compared with ranitidine to determine rates of ventilator-associated pneumonia and gastrointestinal bleeding [22]. Patients were followed until death, discharge, or clinical suspicion of ventilator-associated pneumonia as determined by the attending intensivist. Bronchoalveolar lavage or protected specimen brush was indicated for patients with a clinical suspicion of ventilator-associated pneumonia. A diagnosis of ventilator-associated pneumonia was considered only in patients who were receiving mechanical ventilation or who stopped receiving ventilation for less than 48 hours. In the absence of a reference standard for diagnosing pneumonia in critically ill patients [23, 24], each patient's clinical, laboratory, and radiographic data were independently reviewed by one of four pairs of adjudicators blinded to treatment group. The readers in each adjudication pair decided on the presence or absence of ventilator-associated pneumonia, resolving any disagreement through discussion. Consensus was achieved on all cases.

The adjudicated outcome was used for the primary analysis [177 cases]. However, each case of pneumonia was classified according to four additional definitions: 1) the bedside clinician's diagnosis [233 cases]; 2) the modified Centers for Disease Control and Prevention criteria [25], which require a new radiographic infiltrate persistent for 48 hours or more plus a body temperature greater than 38.5 °C or less than 35.0 °C, a leukocyte count of more than 10 cells x 109/L or less than 3 cells x 109/L, purulent sputum or change in character of sputum, or isolation of pathogenic bacteria from an endotracheal aspirate [211 cases]; 3) a Clinical Pulmonary Infection score of 7 or more [26] [194 cases]; or 4) a positive culture from bronchoalveolar lavage (>104 colony-forming units/mL) or protected specimen brush (<103 colony-forming units/mL) (97 cases).

Statistical Analysis

We expressed continuous variables as the mean (±SD) or as the median and interquartile range if their distribution was skewed. We used the Student t-test to compare continuous variables and the chi-square test to compare proportions. All statistical tests were two-tailed.

We performed a forward stepwise Cox proportional-hazards regression analysis to evaluate potential risk factors for ventilator-associated pneumonia. The Cox model assesses the effect of each risk factor on the hazard rate of ventilator-associated pneumonia over time, adjusted for other factors in the model and allowing for censoring because of death or discharge. The hazard function in the Cox model can be used to estimate the event rate per day over the duration of stay in the intensive care unit.

Independent variables recorded at baseline included age; sex; primary diagnosis; medical or surgical status; hospital admission in the fall or winter compared with spring or summer; location before admission to the intensive care unit; treatment center; Acute Physiology and Chronic Health Evaluation II score; Acute Physiology score; Multiple Organ Dysfunction score [27]; Glasgow Coma Scale score; and chronic comorbid conditions, such as alcoholism, a smoking history of 10 or more pack-years, asthma, bronchiectasis, pulmonary fibrosis, cancer, and HIV infection; organ transplantation; and recent corticosteroid therapy or chemotherapy. Additional independent variables evaluated daily throughout the intensive care unit stay were classified as illness severity measures (daily Multiple Organ Dysfunction score and change in Multiple Organ Dysfunction score from baseline), ventilation variables (mechanical ventilation, change or reinsertion of endotracheal tube, discontinuation and reinstitution of mechanical ventilation, and tracheostomy), nutritional variables (nasoenteral nutrition, gastrostomy feeding, jejunostomy feeding, enteral nutrition through any route, central parenteral nutrition, peripheral parenteral nutrition, and insulin requirement of more than 15 U/d), witnessed aspiration, and drug exposure (stress-ulcer prophylaxis with ranitidine or sucralfate, paralytic agents, and antibiotics).

The Multiple Organ Dysfunction Score combines measures of physiologic dysfunction in six domains: the cardiovascular system (heart rate x right atrial pressure/mean arterial pressure), pulmonary system (PaO2:FIO2 ratio), the renal system (serum creatinine concentration), the hepatic system (serum bilirubin level), the hematologic system (platelet count), and the central nervous system (Glasgow Coma Scale score) [25]. These continuous variables are constructed in 5 categories so that 0 represents normal function and 4 reflects marked physiologic derangement and is associated with a mortality rate greater than 50%. Composite scores provide a quantitative measure of global physiologic dysfunction at a discrete point in the intensive care unit stay. For individual domains, either the raw data or their score provides a measure of dysfunction in the system of interest.

Variables that were associated with ventilator-associated pneumonia in the univariable analysis and had a P value less than 0.10 were entered into a multivariable regression analysis. Factors were considered significant if the P value was less than 0.05 in the multivariable analysis. We calculated risk ratios and 95% CIs for all significant predictors of ventilator-associated pneumonia in the multivariable analysis using all five definitions.

We tested for all pairwise interactions between significant risk factors in the multivariable model. We also tested for interactions between predictors in the multivariable model and factors that were significant in the univariable analysis. Finally, we investigated the possibility that the effects of risk factors may vary over the duration of stay in the intensive care unit; this was done by using a nonproportional Cox model testing the interaction of each variable in the final model with time. For example, we hypothesized that the influence of antibiotics on ventilator-associated pneumonia may vary over time. Time was considered both a continuous variable and a discretized variable by using 3-day and 5-day intervals. We did not consider antibiotics administered 24 hours before the diagnosis of ventilator-associated pneumonia, so that drugs prescribed in response to early ventilator-associated pneumonia would be excluded [28].

Role of Study Sponsor

Our funding sources had no role in the acquisition, analysis, or interpretation of data or in the submission of this report.


Results
space
up arrowTop
up arrowMethods
dotResults
down arrowDiscussion
down arrowAuthor & Article Info
down arrowReferences

Of the 1200 patients enrolled in this study, 186 were excluded (85 were discharged, 71 died, and 30 had pneumonia in the first 48 hours), leaving 1014 patients ventilated for 48 hours or more who were free of pneumonia at admission to the intensive care unit. Of these patients, 177 (17.5%) developed ventilator-associated pneumonia 9.0 ± 5.9 days after admission (median, 7 days [interquartile range, 5 to 10 days]). The characteristics of patients with and without ventilator-associated pneumonia are shown in Table 1. The total duration of mechanical ventilation among patients with ventilator-associated pneumonia was 19.3 ± 16.0 days (median, 15 days [interquartile range, 9 to 23 days]) compared with 10.2 ± 10.5 days (median, 7 days [interquartile range, 4 to 11 days]) in other patients (P < 0.001). Among the 177 patients with ventilator-associated pneumonia, 131 (74.0%) had bronchoscopic testing with bronchoalveolar lavage or protected specimen brush. Patients in the following admitting diagnostic categories had ventilator-associated pneumonia: cardiovascular disease (41 of 277 patients [14.8%]), respiratory disease (24 of 157 patients [15.3%]), thoracic or abdominal surgery (18 of 130 patients [13.9%]), gastrointestinal disease (4 of 31 patients [12.9%]), central nervous system disease (39 of 164 patients [23.8%]), trauma (31 of 119 patients [26.1%]), burns (7 of 10 patients [70%]), sepsis (5 of 63 patients [7.9%]), transplantation (0 of 16 patients [0%]), and metabolic or other disease (8 of 47 patients [17.0%]) (P < 0.001 for difference across groups).


View this table:
[in this window]
[in a new window]
 
Table 1. Comparison of Patients with and Those without Ventilator-Associated Pneumonia*

 

The cumulative risk for developing ventilator-associated pneumonia over successive days in the intensive care unit is shown in Figure 1. The overall incidence of ventilator-associated pneumonia was 14.8 cases per 1000 ventilator-days. The daily risk for developing ventilator-associated pneumonia increased until day 5, then decreased over the duration of stay in the intensive care unit (Figure 2). The risk per day was approximately 3.3% at day 5, 2.3% at day 10, and 1.3% at day 15.



View larger version (11K):
[in this window]
[in a new window]
 
Figure 1. Proportion of patients free of pneumonia during their stay in the intensive care unit.

 


View larger version (11K):
[in this window]
[in a new window]
 
Figure 2. Hazard rate for ventilator-associated pneumonia during the stay in the intensive care unit. The hazard function presents the conditional probability of ventilator-associated pneumonia in the next day, given that a patient is event free. Estimation of the hazard function shows the event rate per day over the duration of ventilation.

 

Factors associated with ventilator-associated pneumonia in the univariable analysis were age, male sex, primary admitting diagnosis, intensive care unit admission from the emergency department, low Glasgow Coma Scale score, increased Multiple Organ Dysfunction score compared with that at admission, mechanical ventilation in the previous 24 hours, nasoenteral nutrition, enteral nutrition by any route, witnessed aspiration, administration of paralytic agents, and absence of exposure to antibiotics (Table 2). Administration of stress-ulcer prophylactic agents was not a predictor of ventilator-associated pneumonia in the univariable analysis; this is in keeping with our randomized trial results showing that patients receiving ranitidine had a rate of ventilator-associated pneumonia similar to that seen in patients receiving sucralfate (relative risk, 1.18 [95% CI, 0.92 to 1.51]) but had a lower rate of gastrointestinal bleeding (relative risk, 0.44 [CI, 0.21 to 0.92]) [22].


View this table:
[in this window]
[in a new window]
 
Table 2. Risk Factors for Ventilator-Associated Pneumonia*

 

Independent predictors included a primary admitting diagnosis of burns (risk ratio, 5.09 [CI, 1.52 to 17.03]), trauma (risk ratio, 5.0 [CI, 1.91 to 13.11]), central nervous system disease (risk ratio, 3.4 [CI, 1.31 to 8.81]), respiratory disease (risk ratio, 2.79 [CI, 1.04 to 7.51]), cardiac disease (risk ratio, 2.72 [CI, 1.05 to 7.01]), mechanical ventilation in the previous 24 hours (risk ratio, 2.28 [CI, 1.11 to 4.68], witnessed aspiration (risk ratio, 3.25 [CI, 1.62 to 6.50]), and paralytic agents (risk ratio, 1.57 [CI, 1.03 to 2.39]). Exposure to antibiotics conferred protection (risk ratio, 0.37 [CI, 0.27 to 0.51]) (Table 2). Results are adjusted for center, which was significant in the final model (P = 0.007). Patients with and those without ventilator-associated pneumonia are described according to the time-dependent independent predictors in Table 1. Risk factors were the same when ventilator-associated pneumonia was diagnosed according to the bedside clinician's assessment, the Centers for Disease Control and Prevention definition, a Clinical Pulmonary Infection score of 7 or more, and positive culture from bronchoalveolar lavage (>104 colony-forming units/mL) or protected specimen brush (>103 colony-forming units/mL).

No significant interactions were seen between the independent predictors in the multivariable analysis or the independent predictors and the significant predictors found in the univariable analysis. Evaluation of risk factors in the nonproportional hazards model demonstrated that only the effect of antibiotics changed statistically over time. The risk ratio of ventilator-associated pneumonia associated with antibiotics was 0.30 (CI, 0.17 to 0.52) at day 5, 0.43 (CI, 0.21 to 0.87) at day 10, 0.62 (CI, 0.24 to 1.62) at day 15, and 0.89 (CI, 0.25 to 3.13) at day 20. The CIs around these risk ratios widen as the duration of stay in the intensive care unit increases because of the small number of patients and the low proportion of ventilator-associated pneumonia outcomes observed late after intensive care unit admission. Of all cases of ventilator-associated pneumonia, 40.1% developed before day 5, 41.2% developed during days 6 to 10, 11.3% developed during days 11 to 15, 2.8% developed during days 16 to 20, and 4.5% developed after day 21.

Antibiotics administered included cephalosporins (62.9%), penicillin derivatives (31.4%), aminoglycosides (23.6%), metronidazole (20.1%), macrolides (13.4%), quinolones (10.7%), sulfa derivatives (8.9%), miscellaneous drugs (16.5%), antifungal agents (7.6%), and antiviral agents (3.3%) (the latter two agents were not included in the antibiotic analysis). Patients with ventilator-associated pneumonia received fewer antibiotics and were exposed for a shorter time than patients without ventilator-associated pneumonia. When analyzed according to the cumulative number of antibiotics administered, the risk ratio was 0.94 (CI, 0.92 to 0.97) for each antibiotic prescribed.


Discussion
space
up arrowTop
up arrowMethods
up arrowResults
dotDiscussion
down arrowAuthor & Article Info
down arrowReferences

We examined the incidence of and risk factors for ventilator-associated pneumonia in a cohort of 1014 patients. The risk for developing ventilator-associated pneumonia increased cumulatively, with an overall rate of 14.8 cases per 1000 ventilator-days. However, we found ventilator-associated pneumonia rates of approximately 3% per day in the first week of mechanical ventilation, 2% per day in the second week, and 1% per day in the third week and beyond. This decreasing hazard reflects the high risk for early ventilator-associated pneumonia in ventilated patients and suggests that long-term survivors are patients at lower intrinsic risk for ventilator-associated pneumonia. Other studies have emphasized a high risk for ventilator-associated pneumonia in the first week of mechanical ventilation [20, 29]. Early-onset pneumonia may account for as many as 50% of cases of ventilator-associated pneumonia, and most etiologic organisms represent common respiratory tract pathogens or normal oropharyngeal flora [2, 3, 15].

Like other investigators [17], we found aspiration to be an independent risk factor for ventilator-associated pneumonia. Pharyngeal aspiration in patients with depressed consciousness is common [30]. Impaired airway reflexes [2, 15] and neuromuscular disease [15] in a heterogeneous group of spontaneously breathing and mechanically ventilated patients were documented as risk factors for nosocomial pneumonia. However, the identification of muscle relaxants as an independent risk factor for ventilator-associated pneumonia has not been demonstrated in studies of mechanically ventilated patients. Although the association was seen in a univariable analysis of 277 ventilated patients [18], two smaller studies found no association [16, 20]. In an observational study of 66 patients with head trauma, 40% of those who received thiopental and 18% of those who did not receive thiopental developed ventilator-associated pneumonia [31]. Paralytic agents and sedatives may predispose to ventilator-associated pneumonia by decreasing the cough reflex, reducing endotracheal secretion clearance, or impairing gut motility.

The relation between administration of antibiotics and occurrence of ventilator-associated pneumonia is complex. Antibiotics were associated with an increased risk for ventilator-associated pneumonia in a cohort study of 320 patients [18]; however, other investigators found that antibiotics administered during the first 8 days were associated with a reduced risk for early-onset ventilator-associated pneumonia in patients with ineffective subglottic secretion drainage [20]. Using different metrics for antibiotic exposure, we found antibiotic administration to be associated with lower rates of ventilator-associated pneumonia (Table 1). The inverse relation between antibiotic use and ventilator-associated pneumonia is consistent with results of randomized trials of selective digestive decontamination, recently summarized in an updated systematic review from the Cochrane Collaboration [32]. Selective digestive decontamination confers a large, clinically important, and statistically significant reduction in lower respiratory tract infections (common odds ratio, 0.35 [CI, 0.29 to 0.41]) [33]. With respect to mortality, the combination of topical and systemic antibiotic prophylaxis was associated with lower mortality (common odds ratio, 0.80 [CI, 0.69 to 0.93]), whereas topical antibiotics only were not (common odds ratio, 1.01 [CI, 0.84 to 1.22]). That systemic antibiotics may protect against ventilator-associated pneumonia is also consistent with results from a recent controlled trial by Sirvent and colleagues [34], who showed that a short course of cephalosporin prophylaxis was associated with a lower rate of ventilator-associated pneumonia in patients with structural coma. We demonstrated that the apparent protective effect of antibiotics disappears after 2 to 3 weeks. Sparse data preclude extrapolation beyond this point; however, an increased risk for ventilator-associated pneumonia cannot be excluded, and prolonged antibiotic administration in intensive care unit patients is expected to favor selection and subsequent colonization with resistant pathogens [35].

We found that nasoenteral nutrition and enteral nutrition by any route were associated with ventilator-associated pneumonia in univariable analysis but not multivariable analysis. Enteral nutrition delivered by nasogastric tube is associated with gastric and endotracheal colonization, which may predispose to ventilator-associated pneumonia [36-38]. In addition, nasal instrumentation favors the development of sinusitis [39]. Trends toward higher rates of sinusitis and pneumonia were found in randomized trials of oral compared with nasal endotracheal intubation [40-43]. Although the incidence of pneumonia in proximally compared with distally delivered feeds was similar in patients receiving gastric and jejunal nutrition (2 of 19 patients compared with 0 of 19 patients) [44], the association between nutrition and ventilator-associated pneumonia warrants further evaluation in large trials examining the sites of intubation and nutritional delivery.

We did not systematically collect data on body position. A causal relation between ventilator-associated pneumonia and body position has been suggested by documentation of supine positioning as an independent predictor of ventilator-associated pneumonia in regression analysis [18], observational data on gastric colonization and ventilator-associated pneumonia [45], and results of three randomized trials showing that patients nursed in the supine rather than the semirecumbent position had a significantly higher rate of aspiration demonstrated scintigraphically [33, 46, 47]. However, a systematic review of this issue shows that most studies using regression modeling to examine risk factors for ventilator-associated pneumonia have not found this association with body position [48]. Therefore, this diverse evidence is consistent with, but not necessarily proof of, the gastropulmonary route of infection.

Because our results were derived from a randomized trial that enrolled patients who received ventilation for at least 48 hours, not all patients at risk for ventilator-associated pneumonia were included. Specifically, we excluded patients on admission who were breathing spontaneously or had pneumonia and patients who required ventilation but were likely to die or be extubated and discharged within 48 hours. We previously documented that participating physicians were approximately 90% accurate at predicting a duration of ventilation of more than 48 hours [49]. Our purpose was not to examine risk factors for ventilator-associated pneumonia due to particular microorganisms [47, 50, 51], risk factors for death in patients with ventilator-associated pneumonia [52-54], risk factors for attributable ventilator-associated pneumonia mortality [55], or the relation between mechanical ventilation and intensive care unit-acquired infection [1].

Strengths of our study include use of a national multicenter database and examination of acute and chronic health variables, demographic data, and several time-dependent factors to evaluate their relation to ventilator-associated pneumonia. Both independent and dependent variables were collected prospectively; outcomes were determined without knowledge of the predictor variables, and vice versa [56]. Our sample size was larger than those in previous studies. We used a definition of ventilator-associated pneumonia that was established through adjudication of all suspected cases and that incorporated radiographic, clinical, and bronchoscopic criteria. In the absence of a reference standard for ventilator-associated pneumonia, we validated our findings by using five definitions of ventilator-associated pneumonia. We used the more powerful Cox proportional-hazards analysis rather than logistic regression to retain information on the exact timing of ventilator-associated pneumonia, taking censoring into account. Modeling the effect of each independent risk factor over time shows that the apparent protective effect of antibiotics attenuates as the time in the intensive care unit increases.

Risk factors offer prognostic information about the probability of developing lung infection in individual patients and in populations. They help us understand some of the pathophysiologic mechanisms that predispose to pneumonia, and these insights may lead to development of effective preventive strategies [45]. Finally, risk stratification can highlight which patients may be most likely to benefit from pneumonia prophylaxis. We found several potentially amenable risk factors for ventilator-associated pneumonia. Inferences about fixed and variable risk factors are increased when associations are strong, independently predictive, reproducibly demonstrated, and biologically plausible and when they are validated by using different outcome definitions. When variable risk factors are modified in experiments and found to influence the target outcome, these factors may be viewed as causal. Pneumonia prevention approaches focused on nutrition [9], and the ventilator circuit and secretion management [8] have been studied in 28 randomized, controlled trials to date. Building on the results of risk factor studies of ventilator-associated pneumonia, future prevention trials may consider diverse strategies related to nutrition, sedation, paralytic agents, and systemic antibiotic therapy targeted at high-risk populations with long-term follow-up for emergence of resistant organisms.

Drs. Walter and Guyatt and Ms. Griffith: Department of Clinical Epidemiology, McMaster University Medical Center, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada.

Dr. R. Cook: Department of Statistics and Actuarial Science, University of Waterloo, 200 University Avenue, Waterloo, Ontario N2L 361, Canada.

Dr. Leasa: Department of Medicine, London Health Sciences Centre-University Campus, 339 Windermere Road, London, Ontario N6A 5A5, Canada.

Dr. Brun-Buisson: Department of Medical Intensive Care and Infection Control Unit, Hopital Henri Mondor, 51, avenue du Mal de Lattre de Tassigny, 94010 Creteil Cedex, France.


Author and Article Information
space
up arrowTop
up arrowMethods
up arrowResults
up arrowDiscussion
dotAuthor & Article Info
down arrowReferences

For the Canadian Critical Care Trials Group
From McMaster University, Hamilton, University of Waterloo, Waterloo, and University of Western Ontario, London, Ontario, Canada; and Hopital Henri Mondor, Universite Paris-Val de Marne, Creteil, France.
Acknowledgments: The authors thank members of the Canadian Critical Care Trials Group, particularly the Pneumonia Adjudication Committee, for their support of this study. They also thank the research nurses who collected the data and Ms. Peggy Austin for help with coordinating the study.
Grant Support: By the Medical Research Council of Canada and Hoechst Marion Roussel, Inc. Dr. D. Cook is a Career Scientist of the Ontario Ministry of Health. Dr. Walter is a National Health Scientist, National Health Research and Development Program, Health Canada. Dr. R. Cook is a Scholar of the Medical Research Council of Canada.
Requests for Reprints: Deborah J. Cook, MD, Department of Medicine, St. Joseph's Hospital, 50 Charlton Avenue East, Hamilton, Ontario L8N 4A6, Canada; e-mail, debcook@fhs.csu.mcmaster.ca.
Current Author Addresses: Drs. D. Cook and Jaeschke: Department of Medicine, St. Joseph's Hospital, 50 Charlton Avenue East, Hamilton, Ontario L8N 4A6, Canada.


References
space
up arrowTop
up arrowMethods
up arrowResults
up arrowDiscussion
up arrowAuthor & Article Info
dotReferences

1. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in intensive Care (EPIC) study. EPIC International Advisory Committee. JAMA. 1995; 274:639-44.

2. Chevret S, Hemmer M, Carlet J, Langer M. Incidence and risk factors of pneumonia acquired in intensive care units. Results from a multicenter prospective study on 996 patients. European Cooperative Group on Nosocomial Pneumonia. Intensive Care Med. 1993; 19:256-64.

3. Alvarez-Lerma F, Palmoar M, Martinez-Pellus AE, et al. Aetiology and diagnostic techniques in intensive care-acquired pneumonia: a Spanish multicenter study. Clin Intensive Care. 1997; 8:164-70.

4. Papazian L, Bregeon F, Thirion X, Gregoire R, Saux P, Denis JP, et al. Effect of ventilator-associated pneumonia on mortality and morbidity. Am J Respir Crit Care Med. 1996; 154:91-7.

5. Fagon JY, Chastre J, Vuagnat A, Trouillet JL, Novara A, Gibert C. Nosocomial pneumonia and mortality among patients in intensive care units. JAMA. 1996; 275:866-9.

6. Craven DE, Kunches LM, Lichtenberg DA, Kollisch NR, Barry MA, Heeren TC, et al. Nosocomial infection and fatality in medical and surgical intensive care unit patients. Arch Intern Med. 1988; 148:1161-8.

7. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med. 1993; 94:281-8.

8. Cook DJ, De Jonghe B, Brochard L, Brun-Buisson C. Influence of airway management on ventilation associated pneumonia: evidence from randomized trials. JAMA. 1998; 279:781-7.

9. Cook DJ, De Jonghe B, Heyland DK. The relation between nutrition and nosocomial pneumonia: Randomized trials in critically ill patients. Crit Care. 1997; 1:3-9.

10. Hanson LC, Weber DJ, Rutala WA. Risk factors for nosocomial pneumonia in the elderly. Am J Med. 1992; 92:161-6.

11. Celis R, Torres A, Gatell JM, Almela M, Rodriguez-Roisin R, Agusti-Vidal A. Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest. 1988; 93:318-24.

12. Joshi N, Localio AR, Hamory BH. A predictive risk index for nosocomial pneumonia in the intensive care unit. Am J Med. 1992; 93:135-42.

13. Cunnion KM, Weber DJ, Broadhead WE, Hanson LC, Pieper CF, Rutala WA. Risk factors for nosocomial pneumonia: comparing adult critical-care populations. Am J Respir Crit Care Med. 1996; 153:158-62.

14. Kropec A, Schulgen G, Just H, Geiger K, Schumacher M, Daschner F. Scoring system for nosocomial pneumonia in ICUs. Intensive Care Med. 1996; 22:1155-61.

15. Mosconi P, Langer M, Cigada M, Mandelli M. Epidemiology and risk factors of pneumonia in critically ill patients. Intensive Care Unit Group for Infection Control. Eur J Epidemiol. 1992; 7:320-7.

16. Craven DE, Kunches LM, Kilinsky V, Lichtenberg DA, Make BJ, McCabe WR. Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation. Am Rev Respir Dis. 1986; 133:792-6.

17. Torres A, Aznar R, Gatell JM, Jimenez P, Gonzalez J, Ferrer A, et al. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis. 1990; 142:523-8.

18. Kollef M. Ventilator-associated pneumonia: a multivariate analysis. JAMA. 1993; 270:1965-70.

19. Elatrous S, Boujdaria R, Merghli S, Ouanes L, Boussarsar M, Nouira S, et al. Incidence and risk factors of ventilator-associated pneumonia: a one-year prospective survey. Clin Intensive Care. 1996; 7:276-81.

20. Rello J, Sonora S, Jubert P, Artigas A, Rue M, Valles J. Pneumonia in intubated patients: role of respiratory airway care. Am J Respir Crit Care Med. 1996; 154:111-5.

21. Kollef MH, Von Harz B, Prentice D, Shapiro SD, Silver P, St John R, et al. Patient transport from intensive care increases the risk of developing ventilator-associated pneumonia. Chest. 1997; 112:765-73.

22. Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastroin-testinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med. 1998; 338:791-7.

23. Niederman MS, Torres A, Summer W. Invasive diagnostic testing is not needed routinely to manage suspected ventilated-associated pneumonia. Am J Respir Crit Care Med. 1994; 150:565-9.

24. Chastre J, Fagon JY. Invasive diagnostic testing should be routinely used to manage ventilated patients with suspected pneumonia. Am J Respir Crit Care Med. 1994; 150:570-4.

25. CDC definitions for nosocomial infections, 1988. Am Rev Respir Dis. 1989; 139:1058-9.

26. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew RD, Suter PM. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis. 1991; 143(5 Pt 1):1121-9.

27. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995; 23:1638-52.

28. Timsit JF, Misset B, Renaud B, Goldstein FW, Carlet J. Effect of previous antimicrobial therapy on the accuracy of the main procedures used to diagnose nosocomial pneumonia in patients who are using ventilation. Chest. 1995; 108:1036-40.

29. Langer M, Mosconi P, Cigada M, Mandelli M. Long-term respiratory support and risk of pneumonia in critically ill patients. Intensive Care Unit Group of Infection Control. Am Rev Respir Dis. 1989; 140:302-5.

30. Huxley EJ, Viroslav J, Gray WR, Pierce AK. Pharyngeal aspiration in normal adults and patients with depressed consciousness. Am J Med. 1978; 64:564-8.

31. Braun SR, Levin AB, Clark KL. Role of corticosteroids in the development of pneumonia in mechanically ventilated head-trauma victims. Crit Care Med. 1986; 14:198-201.

32. Liberati A, D'Amico R, Pifferi S, Leonetti C, Torri V, Brazzi L, et al. Antibiotic prophylaxis in adult patients treated in intensive care units. In: Douglas R, Bridges-Webb C, Glasziou P, Lozano J, Steinhoff M, Wang E, eds. Acute Respiratory Infections Module of the Cochrane Database of Systematic Reviews. Cochrane Collaboration. Cochrane Library. 1997; 3:1-14.

33. Torres A, Serra-Batiles J, Ros E, Piera C, Puig de la Bellacasa J, Cobos A, et al. Pulmonary aspiration of gastric contents in patients receiving mechanical ventilation: the effect of body position. Ann Intern Med. 1992; 116:540-3.

34. Sirvent JM, Torres A, El-Ebiary M, Castro P, de Batile J, Bonet A. Protective effect of intravenously administered cefuroxime against nosocomial pneumonia in patients with structural coma. Am J Respir Crit Care Med. 1997; 155:1729-34.

35. Rello J, Ausina V, Ricart M, Puzo C, Quintana E, Net A, et al. Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia. Intensive Care Med. 1994; 20:193-8.

36. Atherton ST, White DJ. Stomach as source of bacteria colonizing respiratory tract during artificial respiration. Lancet. 1978; 2:968-9.

37. Pingelton SK, Hinthorn DR, Liu C. Enteral nutrition in patients receiving mechanical ventilation. Multiple sources of tracheal colonization include the stomach. Am J Med 1986; 80:827-32.

38. Bonten MJ, Gaillard CA, de Leeuw PW, Stobberingh EE. Role of colonization of the upper intestinal tract in the pathogenesis of ventilator associated pneumonia. Clin Infect Dis. 1997; 24:309-19.

39. Rouby JJ, Laurent P, Gosnach M, Cambau E, Lamas G, Zouaoui A, et al. Risk factors and clinical relevance of nosocomial maxillary sinusitis in the critically ill. Am J Respir Crit Care Med. 1994; 150:776-83.

40. Salord F, Gaussorgues P, Marti-Flich J, Sirodot M, Allimant C, Lyonnet D, et al. Nosocomial maxillary sinusitis during mechanical ventilation: a prospective comparison of orotracheal versus the nasotracheal route for intubation. Intensive Care Med. 1990; 16:390-3.

41. Michelson A, Kamp HD, Schuster B. [Sinusitis in long-term intubated, intensive care patients; nasal versus oral intubation]. Anaesthesist. 1991; 40:100-4.

42. Holzapfel L, Chevret S, Madinier G, Ohen F, Demingeon G, Coupry A, et al. Influence of long-term oro- or nasotracheal intubation on nosocomial maxillary sinusitis and pneumonia: results of a prospective, randomized, clinical trial. Crit Care Med. 1993; 21:1132-8.

43. Rouby JJ, Laurent P, Gosnach M, Cambeau E, Lamas G, Zouaoui A, et al. Risk factors and clinical relevance of nosocomial maxillary sinusitis in the critically ill. Am Rev Respir Crit Care Med. 1994; 150:776-83.

44. Montecalvo MA, Steger KA, Farber HW, Smith BF, Dennis RC, Fitzpatrick GF, et al. Nutritional outcome and pneumonia in critical care patients randomized to gastric versus jejunal tube feedings. The Critical Care Research Team. Crit Care Med. 1992; 20:1377-87.

45. Heyland D, Mandell LA. Gastric colonization by gram-negative bacilli and nosocomial pneumonia in the intensive care unit patient. Evidence for causation. Chest. 1992; 101:87-93.

46. Ibanez J, Penafiel A, Raurich JM, Marse P, Jorda R, Mata F. Gastroesophageal reflux in intubated patients receiving enteral nutrition: effect of supine and semirecumbent positions. JPEN J Parenter Enteral Nutr. 1992; 16:419-22.

47. Orozco-Levi M, Torres A, Ferrer M, Piera C, el-Ebiary M, de la Bellacasa JP, et al. Semirecumbent position protects from pulmonary aspiration but not completely from gastroesophageal reflux in mechanically ventilated patients. Am J Respir Crit Care Med. 1996; 152(4 Pt 1):1387-90.

48. Cook DJ, Kollef MH. Risk factors for ICU-acquired pneumonia. JAMA. 1998; 279:1605-6.

49. Cook DJ, King D. How accurate are physician estimates of length of ICU stay and mechanical ventilation? The Canadian Critical Care Trials Group. Am J Respir Crit Care Med. 1994; 149:A640.

50. Rello J, Ricart M, Ausina V, Net A, Prats G. Pneumonia due to Haemophilus influenzae among mechanically ventilated patients. Incidence, outcome, and risk factors. Chest. 1992; 102:1562-5.

51. Baraibar J, Correa H, Mariscal D, Gallego M, Valles J, Rello J. Risk factors for infection by Acinetobacter baumannii in intubated patients with nosocomial pneumonia. Chest. 1997; 112:1050-4.

52. Kollef MH, Silver P, Murphy DM, Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 1995; 108:1655-62.

53. Timsit JF, Chevret S, Valcke J, Misset B, Renaud B, Goldstein FW, et al. Mortality of nosocomial pneumonia in ventilated patients: influence of diagnostic tools. Am J Respir Crit Care Med. 1996; 154:116-23.

54. Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV Jr. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest. 1996; 109:1019-29.[Abstract/Free Full Text]

55. Rello J, Ausina V, Ricart M, Castella J, Prats G. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest. 1993; 104:1230-5.

56. Laupacis A, Sekar N, Stiell IG. Clinical prediction rules. A review and suggested modifications of methodological standards. JAMA. 1997; 277:488-94.

Related articles in Annals:

Letters
Ventilator-Associated Pneumonia in Critically Ill Patients
Bruce Kramer
Annals 1999 130: 1027-1028. [Full Text]  

Letters
Ventilator-Associated Pneumonia in Critically Ill Patients
Deborah Cook
Annals 1999 130: 1028. [Full Text]  



This article has been cited by other articles:


Home page
JAMAHome page
M. H. Kollef, B. Afessa, A. Anzueto, C. Veremakis, K. M. Kerr, B. D. Margolis, D. E. Craven, P. R. Roberts, A. C. Arroliga, R. D. Hubmayr, et al.
Silver-Coated Endotracheal Tubes and Incidence of Ventilator-Associated Pneumonia: The NASCENT Randomized Trial
JAMA, August 20, 2008; 300(7): 805 - 813.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
R. G. Masterton, A. Galloway, G. French, M. Street, J. Armstrong, E. Brown, J. Cleverley, P. Dilworth, C. Fry, A. D. Gascoigne, et al.
Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy
J. Antimicrob. Chemother., July 1, 2008; 62(1): 5 - 34.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
D. Cook MD, F. Lauzier MD, M. G. Rocha MD, M. J. Sayles RN, and S. Finfer MD
Serious adverse events in academic critical care research
Can. Med. Assoc. J., April 22, 2008; 178(9): 1181 - 1184.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
J. Poelaert, P. Depuydt, A. De Wolf, S. Van de Velde, I. Herck, and S. Blot
Polyurethane cuffed endotracheal tubes to prevent early postoperative pneumonia after cardiac surgery: A pilot study.
J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 771 - 776.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
S. Farhath, Z. He, T. Nakhla, J. Saslow, S. Soundar, J. Camacho, G. Stahl, S. Shaffer, D. I. Mehta, and Z. H. Aghai
Pepsin, a Marker of Gastric Contents, Is Increased in Tracheal Aspirates From Preterm Infants Who Develop Bronchopulmonary Dysplasia
Pediatrics, February 1, 2008; 121(2): e253 - e259.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
L. Lorente, S. Blot, and J. Rello
Evidence on measures for the prevention of ventilator-associated pneumonia
Eur. Respir. J., December 1, 2007; 30(6): 1193 - 1207.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
R. Omrane, J. Eid, M. M Perreault, H. Yazbeck, D. Berbiche, A. Gursahaney, and Y. Moride
Impact of a Protocol for Prevention of Ventilator-Associated Pneumonia
Ann. Pharmacother., September 1, 2007; 41(9): 1390 - 1396.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
S. Nseir, C. Di Pompeo, E. Jozefowicz, B. Cavestri, H. Brisson, M. Nyunga, S. Soubrier, and A. Durocher
Relationship between tracheotomy and ventilator-associated pneumonia: a case control study
Eur. Respir. J., August 1, 2007; 30(2): 314 - 320.
[Abstract] [Full Text] [PDF]


Home page
Am J Crit CareHome page
J. Brozek, E. McDonald, F. Clarke, C. Gosse, R. Jaeschke, and D. Cook
Pneumonia Observational Incidence and Treatment: A Multidisciplinary Process Improvement Study
Am. J. Crit. Care., May 1, 2007; 16(3): 214 - 219.
[Abstract] [Full Text] [PDF]


Home page
Biol Res NursHome page
P. V. O'Neal, C. L. Munro, M. J. Grap, and S. M. Rausch
Subglottic Secretion Viscosity and Evacuation Efficiency
Biol Res Nurs, January 1, 2007; 8(3): 202 - 209.
[Abstract] [PDF]


Home page
NEJMHome page
The Canadian Critical Care Trials Group
A Randomized Trial of Diagnostic Techniques for Ventilator-Associated Pneumonia
N. Engl. J. Med., December 21, 2006; 355(25): 2619 - 2630.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
F. Frutos-Vivar, N. D. Ferguson, A. Esteban, S. K. Epstein, Y. Arabi, C. Apezteguia, M. Gonzalez, N. S. Hill, S. Nava, G. D'Empaire, et al.
Risk Factors for Extubation Failure in Patients Following a Successful Spontaneous Breathing Trial
Chest, December 1, 2006; 130(6): 1664 - 1671.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
C. E. O. Baleeiro, P. J. Christensen, S. B. Morris, M. P. Mendez, S. E. Wilcoxen, and R. Paine III
GM-CSF and the impaired pulmonary innate immune response following hyperoxic stress
Am J Physiol Lung Cell Mol Physiol, December 1, 2006; 291(6): L1246 - L1255.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
V. D. Rosenthal, D. G. Maki, R. Salomao, C. A. Moreno, Y. Mehta, F. Higuera, L. E. Cuellar, O. A. Arikan, R. Abouqal, H. Leblebicioglu, et al.
Device-associated nosocomial infections in 55 intensive care units of 8 developing countries.
Ann Intern Med, October 17, 2006; 145(8): 582 - 591.
[Abstract] [Full Text] [PDF]


Home page
Clin. Microbiol. Rev.Home page
S. M. Koenig and J. D. Truwit
Ventilator-Associated Pneumonia: Diagnosis, Treatment, and Prevention
Clin. Microbiol. Rev., October 1, 2006; 19(4): 637 - 657.
[Abstract] [Full Text] [PDF]


Home page
Am J Crit CareHome page
C. L. Munro, M. J. Grap, R.K. Elswick Jr, J. McKinney, C. N. Sessler, and R. S. Hummel III
Oral health status and development of ventilator-associated pneumonia: a descriptive study.
Am. J. Crit. Care., September 1, 2006; 15(5): 453 - 460.
[Abstract] [Full Text] [PDF]


Home page
J Intensive Care MedHome page
K. A. Davis
Ventilator-associated pneumonia: a review.
J Intensive Care Med, July 1, 2006; 21(4): 211 - 226.
[Abstract] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. Koeman, A. J. A. M. van der Ven, E. Hak, H. C. A. Joore, K. Kaasjager, A. G. A. de Smet, G. Ramsay, T. P. J. Dormans, L. P. H. J. Aarts, E. E. de Bel, et al.
Oral Decontamination with Chlorhexidine Reduces the Incidence of Ventilator-associated Pneumonia
Am. J. Respir. Crit. Care Med., June 15, 2006; 173(12): 1348 - 1355.
[Abstract] [Full Text] [PDF]


Home page
Am J Crit CareHome page
S. E. McLean, L. A. Jensen, D. G. Schroeder, N. R. T. Gibney, and N. M. Skjodt
Improving Adherence to a Mechanical Ventilation Weaning Protocol for Critically Ill Adults: Outcomes After an Implementation Program
Am. J. Crit. Care., May 1, 2006; 15(3): 299 - 309.
[Abstract] [Full Text] [PDF]


Home page
Clin. Microbiol. Rev.Home page
D. Church, S. Elsayed, O. Reid, B. Winston, and R. Lindsay
Burn Wound Infections
Clin. Microbiol. Rev., April 1, 2006; 19(2): 403 - 434.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
R. G. Wunderink
Nosocomial Pneumonia, Including Ventilator-associatedPneumonia
Proceedings of the ATS, December 1, 2005; 2(5): 440 - 444.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
E. Kostadima, A. G. Kaditis, E. I. Alexopoulos, E. Zakynthinos, and D. Sfyras
Early gastrostomy reduces the rate of ventilator-associated pneumonia in stroke or head injury patients
Eur. Respir. J., July 1, 2005; 26(1): 106 - 111.
[Abstract] [Full Text] [PDF]


Home page
Am J Crit Care